5SZ7
Carbonic anhydrase IX-mimic in complex with 4-(3-quinolinyl)-benzenesulfonamide
5SZ7 の概要
エントリーDOI | 10.2210/pdb5sz7/pdb |
関連するPDBエントリー | 5SZ0 5SZ1 5SZ2 5SZ3 5SZ4 5SZ5 5SZ6 |
分子名称 | Carbonic anhydrase 2, ZINC ION, 4-(3-quinolinyl)-benzenesulfonamide, ... (5 entities in total) |
機能のキーワード | sulfonamide, inhibitor, zinc-binding, lyase-lyase inhibitor complex, lyase/lyase inhibitor |
由来する生物種 | Homo sapiens (Human) |
細胞内の位置 | Cytoplasm : P00918 |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 29506.74 |
構造登録者 | Bhatt, A.,Mahon, B.P.,Cornelio, B.,McKenna, R. (登録日: 2016-08-12, 公開日: 2016-12-21, 最終更新日: 2024-03-06) |
主引用文献 | Bhatt, A.,Mahon, B.P.,Cruzeiro, V.W.,Cornelio, B.,Laronze-Cochard, M.,Ceruso, M.,Sapi, J.,Rance, G.A.,Khlobystov, A.N.,Fontana, A.,Roitberg, A.,Supuran, C.T.,McKenna, R. Structure-Activity Relationships of Benzenesulfonamide-Based Inhibitors towards Carbonic Anhydrase Isoform Specificity. Chembiochem, 18:213-222, 2017 Cited by PubMed Abstract: Carbonic anhydrases (CAs) are implicated in a wide range of diseases, including the upregulation of isoforms CA IX and XII in many aggressive cancers. However, effective inhibition of disease-implicated CAs should minimally affect the ubiquitously expressed isoforms, including CA I and II, to improve directed distribution of the inhibitors to the cancer-associated isoforms and reduce side effects. Four benzenesulfonamide-based inhibitors were synthesized by using the tail approach and displayed nanomolar affinities for several CA isoforms. The crystal structures of the inhibitors bound to a CA IX mimic and CA II are presented. Further in silico modeling was performed with the inhibitors docked into CA I and XII to identify residues that contributed to or hindered their binding interactions. These structural studies demonstrated that active-site residues lining the hydrophobic pocket, especially positions 92 and 131, dictate the positional binding and affinity of inhibitors, whereas the tail groups modulate CA isoform specificity. Geometry optimizations were performed on each ligand in the crystal structures and showed that the energetic penalties of the inhibitor conformations were negligible compared to the gains from active-site interactions. These studies further our understanding of obtaining isoform specificity when designing small molecule CA inhibitors. PubMed: 27860128DOI: 10.1002/cbic.201600513 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.776 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード